Overview
Explores novel therapeutic strategies to inhibit signaling
Discusses current and next generation antimitotic therapies in cancer
Features up-to-date research
Includes supplementary material: sn.pub/extras
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (8 chapters)
-
Front Matter
-
Back Matter
Keywords
About this book
In recent years, increasing evidence has suggested that abnormal activation of signaling pathways is a critical event in cancer pathogenesis. In particular, activation of these pathways can lead to inappropriate cellular survival, proliferation, pluripotency, invasion, metastasis, and angiogenesis. Thus, understanding the mechanisms by which signaling pathways become subverted in a cancer cell can provide insight into critical events in cancer pathogenesis. Furthermore, as our ability to target specific molecular interactions advances, we now have the ability to design small molecules, protein therapeutics, and other forms of targeted therapies. By focusing on the specific molecular abnormalities in a cancer cell, these agents hold the potential to be much more effective and much less toxic than current cytotoxic therapies.
Editors and Affiliations
Bibliographic Information
Book Title: Signaling Pathways in Cancer Pathogenesis and Therapy
Editors: David A. Frank
DOI: https://doi.org/10.1007/978-1-4614-1216-8
Publisher: Springer New York, NY
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer Science+Business Media, LLC 2012
Hardcover ISBN: 978-1-4614-1215-1Published: 12 November 2011
Softcover ISBN: 978-1-4899-9222-2Published: 26 January 2014
eBook ISBN: 978-1-4614-1216-8Published: 12 November 2011
Edition Number: 1
Number of Pages: VIII, 148
Topics: Cancer Research, Pharmacology/Toxicology